[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hematuria\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hematuria":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,46,78,102,128,157,188,218,244,269,294,319],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100644810","specimen-collection-for-validation-of-uroamp-a-next-generation-sequencing-platform-for-detection-and-surveillance-of-bladder-cancer-100644810",false,"NCT07673016","Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer","INSITE","Inclusion Criteria:\n\nGROUP 1: Bladder Cancer and\u002For Upper Tract UCC\n\n* Male or female ≥ 18 years of age who are scheduled for transurethral resection of bladder tumor (TURBT) and\u002For biopsy of urinary tract or\n* Patients on surveillance who are negative for recurrence or tumor at the time of study enrollment but have had previous urothelial cell carcinoma (UCC) or\n* Patients with muscle invasive bladder cancer (MIBC) or non-muscle invasive bladder cancer (NMIBC) scheduled for NAC and\u002For subsequent radical cystectomy (RC)\n* Able to provide consent prior to diagnostic TURBT, nephroureterectomy, or administration of NAC and\u002For RC\n* Able to provide at least 20cc urine. If patient cannot void sufficient volume of urine, urologist can pull urine from the bladder via catheter or cystoscope. Urine should not be collected immediately after resection\n* Participation in other bladder cancer studies is allowed. Experimental therapy must be documented in the case report forms\n\nGROUP 2: Hematuria Controls\n\n* Male or female ≥ 18 years of age presenting with gross or microscopic hematuria as defined by standard of care\n* No evidence of and\u002For history of bladder cancer, upper tract UCC, kidney cancer and\u002For prostate cancer at the time of collection\n* Able to provide consent\n* Able to provide at least 20cc urine\n* Participation in other studies is allowed. Experimental therapy must be documented in the case report forms\n\nExclusion Criteria:\n\nGROUP 1: Bladder Cancer and\u002For Upper Tract UCC\n\n* Clinical, symptomatic urinary tract infection at time of initial urine collection\n* Unable to provide adequate urine sample\n\nGROUP 2: Hematuria Controls\n\n\\- Evidence and\u002For History of bladder cancer, upper tract UCC, kidney cancer and\u002For prostate cancer at the time of collection","ALL","18 Years",{"count":19,"type":20},2500,"ESTIMATED","OBSERVATIONAL","This is a prospective, multicenter observational study designed to collect urine and tumor biospecimens and associated clinical data from patients undergoing evaluation, treatment, or surveillance for urothelial carcinoma.",[24,25,26,27],"Bladder Cancer","Urothelial Carcinoma (UC)","Hematuria","Upper Tract Urothelial Cancer",[29,30,31,32],"Non-muscle invasive bladder cancer","Muscle invasive bladder cancer","Upper tract urothelial carcinoma","Urine tumor DNA","RECRUITING","2026-06-24",{"date":36,"type":37},"2026-06-29","ACTUAL",{"date":39,"type":37},"2019-10-15",{"date":41,"type":20},"2034-12",{"name":43,"class":44},"Convergent Genomics, Inc.","NETWORK",23,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100626153","optimizing-referral-pathways-for-patients-with-hematuria-and-moderate-severe-proteinuria-100626153","NCT07431931","Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria","Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria - Phase 2: A Quality Improvement Project","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Patients receiving care from any Geisinger primary care provider (record of an encounter with a Geisinger PCP within the last 2 years from date of survey implementation)\n* Patients with high-risk glomerulonephritis features i.e. positive test results for hematuria (urine dipstick result with blood 1+ or greater) and proteinuria (2+ or 3+ protein on dipstick or ACR≥300 mg\u002Fg or PCR ≥500 mg\u002Fg) collected within 12 months of index date.\n\nExclusion Criteria:\n\n* Patients with a nephrologist appointment in the last 12 months before the index date\n* Patients with a prior appointment with a nephrologist within the last 2 years before the positive urinalysis test for hematuria (1+ or greater)\n* Patients with a history of glomerulonephritis and\u002For kidney failure (dialysis or eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m2, or kidney transplantation) at any time during the baseline\n* Patients receiving palliative care at any time during the baseline",{"count":54,"type":20},1200,"INTERVENTIONAL",[57],"NA","The purpose of the study is to evaluate prospectively the impact of an electronic health record (EHR) alert on primary care providers' (PCP) referral to Nephrology of Geisinger patients with high risk signs (blood and protein in the urine) of glomerulonephritis. This will help quantify the relative effectiveness of EHR alerts on PCPs' referral patterns.",[60,61,26,62,63],"Referral and Consultation","Glomerulonephritis","Proteinuria","Kidney Disease",[65],"Hematuria; Proteinuria; Albuminuria; Glomerulonephritis; Clinical Decision Support; EHR Alert; Referral; Nephrology","NOT_YET_RECRUITING","2026-05-07",{"date":69,"type":37},"2026-05-12",{"date":71,"type":20},"2026-11",{"date":73,"type":20},"2027-12",{"name":75,"class":76},"Geisinger Clinic","OTHER",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":55,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":77},"100488928","bladder-cancer-screening-trial-100488928","NCT05646485","Bladder Cancer Screening Trial","Optimal Screening Strategy for Bladder Cancer in at Risk Patients","Inclusion Criteria:\n\n* Age ≥ 50\n* Smoking: ≥15 pack-year smoking history\n* Occupation:≥ 15 years of occupational exposures including: textile worker, painter, dry cleaners\n\nExclusion Criteria:\n\n* Prior history of bladder, kidney, or prostate cancer\n* Prior evaluation of micro or gross hematuria within the last 2 years\n* Do not provide informed consent","50 Years",{"count":87,"type":20},1000,[57],"There is currently no accepted screening strategy for patients at high risk of developing bladder cancer. This study will ask patients to complete a urine test every 6 months for 2 years to help assess if routine screening helps finding bladder cancer at an earlier stage.",[24,91,26,92],"Urothelial Carcinoma","Smoking Cessation","2026-04-27",{"date":95,"type":37},"2026-05-01",{"date":97,"type":37},"2023-05-05",{"date":99,"type":20},"2028-04",{"name":101,"class":76},"University of Texas Southwestern Medical Center",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":110,"minAge":4,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":55,"phases":113,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":77},"100588970","phase-2-rada16-for-aquablation-day-case-100588970","NCT06948331","RADA16 for Aquablation Day Case","A Pilot Proof of Concept Single-arm Study Using PuraStat Following the Aquablation Procedure to Assess Reduction of Hematuria to Allow for Same Day Discharge","RAD","Inclusion Criteria:\n\n• Any man undergoing Aquablation for LUTS due to BPH\n\nExclusion Criteria:\n\n• Unwilling to sign consent","MALE",{"count":112,"type":20},25,[114],"PHASE2","This is a pilot proof of concept single-arm study using PuraStat following Aquablation procedure to assess reduction of hematuria to allow for same day discharge.\n\nThe primary objective is to assess how PuraStat affects post-operative hematuria following Aquablation.\n\nThe secondary objective is to assess the number of patients discharged on the same day based on the hematuria criteria (Grade 0 and Grade I).",[26,117,118],"Benign Prostatic Hyperplasia","Lower Urinary Tract Symptoms","2026-02-25",{"date":121,"type":37},"2026-02-27",{"date":123,"type":20},"2026-04-01",{"date":125,"type":20},"2026-08-01",{"name":127,"class":76},"NYU Langone Health",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":138,"conditions":139,"keywords":143,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":77},"100623315","a-study-of-ward-admissions-for-haematuria-100623315","NCT07395037","A Study of Ward Admissions for Haematuria","Ward AdmiSsion of Haematuria: an Observational mUlticentre sTudy","WASHOUT","Inclusion Criteria:\n\n* Patients are included if they are over 16 years of age or older and admitted to a participating urological secondary care centre\n* admitted as an emergency with haematuria as the primary or secondary diagnosis under the primary or joint care of urology\n\nExclusion Criteria:\n\n* any patients under 16 years of age\n* patients with catheter-related urethral trauma (defined as haemturia immediately after insertion of a urethral catheter that was documented as traumatic by the clinician, with no previous history of haemturia prior to catheter insertion)\n* patients that are in hospital less than 24 hours.",{"count":137,"type":20},1050,"This multicenter, prospective observational study will evaluate national and international practice variations (if present) in the emergency management of patients admitted to hospital with haematuria, inform a consensus guideline for best practice and provide evidence to design an implementation study to optimise haematuria management pathway.",[140,26,141,24,142,91],"Urologic Diseases","Hematuria; Benign","Renal Cancer",[144,145,146,147],"catheter","haematuria","hematuria","irrigation","2026-02-03",{"date":150,"type":37},"2026-02-09",{"date":152,"type":37},"2024-01-01",{"date":154,"type":20},"2026-04-30",{"name":156,"class":76},"British Urology Researchers in Surgical Training",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":164,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":167,"conditions":168,"keywords":173,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":187},"100578964","bladder-epicheck-european-haematuria-study-100578964","NCT06818136","Bladder EpiCheck European Haematuria Study","Evaluation of the Efficacy of Bladder EpiCheck® for the Primary Detection of Urothelial Carcinoma in Subjects Presenting With Haematuria","Inclusion Criteria:\n\n1. Participants aged 45 years or older\n2. Participants who are willing and able to provide written informed consent and adhere to study procedures\n3. Participants presenting with visible and\u002For non-visible haematuria within 6 months prior to study enrollment\n4. Participants scheduled to undergo standard of care cystoscopy for urinary bladder examination within 60 days after study enrollment\n5. Participants who are able to produce at least 10 ml of voided urine\n\nExclusion Criteria:\n\n1. Participants with history of urothelial cancer in the bladder and\u002For upper urinary tract\n2. Participants who had prior cystoscopy for haematuria within the past 2 years\n3. Participants previously enrolled in this study\n4. Participants treated for prostate cancer within the last 12 months\n5. Participants treated for kidney cancer within the last 12 months\n6. Participants with untreated urinary tract infection\n7. Participants with symptomatic urinary tract stones (e.g. flank pain)\n8. Participants on dialysis for end stage renal failure\n9. Participants with a long term urinary catheter\n10. Pregnancy (self-reported)\n11. Participants who, because of medical status, or frailty is not expected to be able to complete the full diagnostic pathway","45 Years",{"count":166,"type":20},800,"The goal of this observational study is to further validate the sensitivity and specificity of Bladder EpiCheck in primary detection of urothelial carcinoma in participants aged 45 years or older presenting with haematuria, compared to cystoscopy and pathology, if performed.\n\nParticipants will provide a voided urine sample, and data from standard of care haematuria work-up will be collected.",[26,169,170,171,172],"Cystoscopy","Urothelial Carcinoma Bladder","Urothelial Carcinoma of the Renal Pelvis and Ureter","Urothelial Carcinoma of the Urinary Bladder",[174,175,176],"urine test","methylation","primary detection","2026-01-21",{"date":179,"type":37},"2026-01-22",{"date":181,"type":37},"2025-06-20",{"date":183,"type":20},"2026-12",{"name":185,"class":186},"Nucleix Ltd.","INDUSTRY",5,{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":16,"minAge":196,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":199,"conditions":200,"keywords":201,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":77},"100616568","study-on-risk-assessment-for-patients-with-microscopic-hematuria-non-visible-blood-in-urine-using-a-urine-marker-test-100616568","NCT07307300","Study on Risk Assessment for Patients With Microscopic Hematuria (Non-Visible Blood in Urine) Using a Urine Marker Test","Risk Stratification of Patients With Non-Visible Hematuria - A Prospective Validation Study Using a Urine Marker-Based Assessment (Xpert® Bladder Cancer Detect)","UroDetect III","Inclusion Criteria:\n\n* Signed consent form after being informed about the study\n* Willing and able to follow the study requirements\n* Non-visible blood in the urine, found within the past 6 months\n* Age over 40 years\n\nExclusion Criteria:\n\n* Previous diagnosis of bladder cancer\n* Too much protein in the urine (shown by urine test)\n* Current urinary tract infection (symptoms like pain or frequent urination, plus bacteria found in urine test)\n* Current pain in the urinary tract or lower belly, pain score greater than 2 on a 0-10 scale\n* Signs of kidney-related blood in the urine (found by special urine test)\n* Bladder examination with a camera (cystoscopy) within the past 12 months\n* Pregnancy\n* Visible blood in the urine within the past year\n* Previous surgery on the urinary tract\n* Previous radiation treatment to the pelvic area\n* Permanent tube or foreign body in the urinary tract (such as a catheter)\n* Participation in another clinical study at the same time or within 30 days before this study\n* Detained under legal or official authority\n* Medical, psychological, or social problems that would make it hard to follow the study requirements\n* Not able to understand the study information well enough to give consent","40 Years",{"count":198,"type":20},1475,"The goal of this clinical study is to learn how well a urine test called Xpert® Bladder Cancer Detect (Xpert BC-D) can help doctors assess the risk of bladder cancer in people with non-visible blood in their urine (microscopic hematuria). The main questions it aims to answer are:\n\n* Can the Xpert BC-D test accurately identify people at higher risk for bladder cancer?\n* Can combining the test results with other clinical information improve risk assessment compared to standard evaluation methods?\n\nParticipants will:\n\n* Have leftover urine from the routine initial evaluation tested with the Xpert® Bladder Cancer Detect assay\n* Complete questionnaires about urinary symptoms using the modified IPSS and ICIQ-FLUT-S forms\n* Attend a first visit for medical evaluation and cystoscopy\n* Attend a follow-up visit 3 to 6 months later for additional testing and questionnaires\n\nThis study includes adults over 40 years of age who have had microscopic hematuria detected within the past six months. People with a history of bladder cancer, urinary tract surgery, or certain other medical conditions, as well as individuals who are currently pregnant, cannot participate.\n\nThe study will be conducted at 20-24 sites in Germany and Austria and will last approximately 27 months, with each participant involved for about 6 months. The results of this study may help doctors better decide which patients need further invasive testing, potentially reducing unnecessary procedures.",[26],[202,203,204,205,206,207,208],"Non-visible hematuria","Microscopic hematuria","Bladder cancer risk","Xpert Bladder Cancer Detect","Risk stratification","Diagnostic assessment","Urinary marker","2025-12-14",{"date":211,"type":37},"2025-12-29",{"date":213,"type":20},"2026-03",{"date":215,"type":20},"2028-06",{"name":217,"class":76},"Christian Bolenz",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":226,"sex":227,"minAge":17,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":77},"100595833","women-with-isolated-acute-cystitis-and-macroscopic-hematuria-is-further-investigation-needed-100595833","NCT07037589","Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed?","Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed? A Prospective Multicenter Study. BLUSH Trial","BLUSH","Inclusion Criteria:\n\n1. Women ≥50 years of age.\n2. Macroscopic hematuria.\n3. Presenting for evaluation within the SCP for macroscopic hematuria.\n4. Ability to provide informed consent.\n\nExclusion Criteria:\n\n1. Prior diagnosis of bladder cancer, renal cancer, or upper tract urothelial carcinoma (UTUC).\n2. Cognitive impairment preventing informed consent.\n3. Ongoing or recent treatment for urological malignancy.\n4. Serious comorbidities affecting participation or safety.\n5. Pregnant women.",true,"FEMALE","110 Years",{"count":230,"type":20},300,"This prospective multicenter observational study evaluates whether women ≥50 years with isolated acute hemorrhagic cystitis (AHC) and macroscopic hematuria require full malignancy workup. All participants undergo standard diagnostics (cystoscopy, CT urography, cytology), with 12-month follow-up for cancer detection. The aim is to identify low-risk patients where invasive investigations may be safely avoided.",[26,233,24,91,142],"Acute Cystitis With Hematuria","2025-11-17",{"date":236,"type":37},"2025-11-21",{"date":238,"type":37},"2025-10-13",{"date":240,"type":20},"2027-08-30",{"name":242,"class":243},"Vastra Gotaland Region","OTHER_GOV",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":16,"minAge":251,"maxAge":252,"enrollmentInfo":253,"targetDuration":255,"studyType":21,"phases":4,"briefSummary":256,"conditions":257,"keywords":258,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":77},"100554875","clinical-and-laboratory-patterns-of-pediatric-gross-hematuria-100554875","NCT06504771","Clinical and Laboratory Patterns of Pediatric Gross Hematuria","Clinical and Laboratory Patterns of Pediatric Gross Hematuria in Sohag University Hospital","Inclusion Criteria:\n\n* lnvestigators will include all patients complaining of gross hematuria between the ages of 1 month up to 16 years.\n\nExclusion Criteria:\n\n* Children with external perineal or genital region bleeding which may falsely cause presence of blood in urine samples.\n* Patients whose legal guardians will refuse participation in the study.\n* Patients with follow up for less than 3 months.","1 Month","16 Years",{"count":254,"type":20},60,"3 Months","Study the demographic, clinical, laboratory and etiological profile of children with gross hematuria and trace the outcome of these patients for at least 3 months follow up.",[26],[259],"Gross hematuria","2024-07-16",{"date":262,"type":37},"2024-07-17",{"date":264,"type":20},"2024-08-01",{"date":266,"type":20},"2025-02",{"name":268,"class":76},"Sohag University",{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":276,"enrollmentInfo":277,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":278,"conditions":279,"keywords":282,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":77},"100552141","performance-evaluation-of-urine-dna-methylation-testing-for-the-detection-of-urothelial-carcinoma-in-patients-with-hematuria-100552141","NCT06469229","Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria","Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria: a Prospective, Multicenter Cohort Study","Inclusion Criteria:\n\n* Aged between 18 and 99 years, with gross or microscopic hematuria (RBC ≥ 3 \u002FHPF or RBC \\> 18 \u002FμL for men, \\> 33 \u002FμL for women).\n* Able to provide 50ml urine for testing before surgery.\n* Consent to participate in the study and sign the informed consent form.\n\nExclusion Criteria:\n\n* With history of any malignancies (including UC).\n* Severe urinary tract infection leading to sepsis.\n* Patients with indwelling catheters, nephrostomy, or cystostomy.\n* Severe liver or kidney failure or other conditions deemed unsuitable for the study.\n* Patients who did not undergo surgical treatment for various reasons.\n* Samples with insufficient DNA content or other quality control failures.\n* Incomplete clinical or pathological data.\n* Patients currently undergoing intravesical or systemic chemotherapy, radiotherapy, immunotherapy, or targeted therapy.","99 Years",{"count":54,"type":20},"Background Urothelial carcinoma (UC) is the most common malignancy of the urinary system. Hematuria is a significant clinical manifestation of UC, often diagnosed through invasive procedures. Urine DNA methylation testing is a promising non-invasive method for early UC detection.\n\nObjectives To evaluate the sensitivity and specificity of urine DNA methylation testing for detecting UC in patients with hematuria, using standard clinical and pathological diagnoses as the gold standard. This study also aim to investigate the association between preoperative urine DNA methylation status and prognosis in UC patients.\n\nFor non-UC patients: Follow up for one year to assess the risk of UC development based on preoperative urine DNA methylation status.\n\nSample Size Calculation Expected sensitivity: 86% Expected specificity: 90% Significance level (Alpha): 0.05 Total participants needed: 1053 (adjusted for 5% dropout rate, 1109 participants will be recruited).\n\nStudy Procedure Enrollment and Sample Collection: Screen patients, obtain consent, collect urine samples.\n\nBlinding and Testing: Blinded sample processing and DNA methylation testing. Unblinding and Analysis: Statistical analysis of sensitivity and specificity. Reporting: Compilation and consolidation of clinical trial reports.\n\nUrine DNA methylation testing is expected to demonstrate high sensitivity and specificity for diagnosing urothelial carcinoma (UC) in patients with hematuria. This non-invasive diagnostic method promises to deliver valuable information, potentially leading to improved patient outcomes.",[26,91,24,280,281],"Ureter Cancer","Renal Pelvis Cancer",[26,91,283,284],"Urine DNA Methylation","Multicenter","2024-07-02",{"date":287,"type":37},"2024-07-05",{"date":289,"type":20},"2024-07-01",{"date":291,"type":20},"2027-12-31",{"name":293,"class":76},"Changhai Hospital",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":226,"sex":110,"minAge":17,"maxAge":301,"enrollmentInfo":302,"targetDuration":4,"studyType":55,"phases":304,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":317,"locationsCount":77},"100486954","phase-3-intra-operative-loop-diuretics-to-improve-same-day-discharge-rates-after-holep-100486954","NCT05620784","Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP","Loop Diuretics During Morcellation to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP)","Inclusion Criteria:\n\n* Males 18 -89 undergoing HoLEP\n* Willing to sign the Informed Consent Form\n* Able to read, understand, and complete patient questionnaires.\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to furosemide or other loop diuretic\n* Anuric patients or patients with liver failure\n* Patients having a concurrent ureteroscopy +\u002F- laser lithotripsy, percutaneous nephrolithotomy, or non-urologic surgery at the time of their HoLEP\n* Anticipated need for perineal urethrostomy at the time of HoLEP\n* Patient not undergoing catheter removal and voiding trial at Northwestern Memorial Hospital","89 Years",{"count":303,"type":20},138,[305],"PHASE3","Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent treatment option for benign prostatic hypertrophy (BPH) as recommended by the American Urological Association (AUA) Guidelines. Loop diuretics (furosemide) have been given historically during the morcellation portion of HoLEP to promote urine production in the post-operative setting and to minimize the impact of fluid absorption during long periods of morcellation. The intra-operative use of 20mg IV furosemide in perioperative HoLEP pathways has been propagated with the dissemination of HoLEP across North America without evidence to support its routine administration. With increasing surgical efficiency from improvements in laser and morcellator technology, the role of intra-operative furosemide is unknown. This study is designed to assess if there is a significant difference in same day discharge rates after Holmium Laser Enucleation of the Prostate (HoLEP) with and without IV furosemide. .",[308,309,26,310],"BPH With Urinary Obstruction","BPH","Same Day Discharge","2023-09-11",{"date":313,"type":37},"2023-09-13",{"date":315,"type":37},"2023-03-01",{"date":264,"type":20},{"name":318,"class":76},"Northwestern University",{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":55,"phases":328,"briefSummary":329,"conditions":330,"keywords":332,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":77},"100518103","safely-reduce-cystoscopic-evaluations-for-hematuria-patients-100518103","NCT06026189","Safely Reduce Cystoscopic Evaluations for Hematuria Patients","SeARCH","Inclusion Criteria:\n\n* Microscopically confirmed microscopic hematuria of voided urine defined as ≥3 erythrocytes per high power field\n* Male patients ≥40 years\n* Female patients ≥50 years\n\nExclusion Criteria:\n\n* History of urothelial bladder- or urinary tract cancer\n* Presence of macroscopic (visible) hematuria\n* Woman who is or may be pregnant",{"count":327,"type":20},1100,[57],"The SeARCH-trial assess the clinical impact of a molecular urine test as a 'urine-first' strategy in the diagnostic workup of patients presenting with microscopic hematuria.",[26,331,91,24],"Urothelial Neoplasm",[333,26,91,24],"Urinary biomarker","2023-08-30",{"date":336,"type":37},"2023-09-06",{"date":338,"type":37},"2023-05-31",{"date":340,"type":20},"2027-05-31",{"name":342,"class":76},"Erasmus Medical Center"]